← Back to Dashboard
Litigation Stage Tracker
Rapid GrowthEmerging
Formation
Active Litigation
Maturation
<45
45–55
55–70
70+
Belviq
OpenFASTPharma
150+
Total Cases
Causation
The CAMELLIA-TIMI 61 clinical trial found a statistically significant increase in cancer diagnoses among patients taking lorcaserin compared to placebo (7.7% vs 7.1% over 5 years), with elevated rates of pancreatic, colorectal, and lung cancers. The FDA requested voluntary withdrawal in February 2020. Plaintiffs allege Eisai and Arena knew of preclinical cancer signals in animal studies but failed to adequately investigate or disclose the risk before market launch in 2012.
Defendants
| Entity | Role | Note |
|---|---|---|
| Eisai Inc. | Manufacturer | Marketed and sold Belviq in the US |
| Eisai Co., Ltd. | Parent Company | Japanese parent corporation — developed lorcaserin |
| Arena Pharmaceuticals | Original Developer | Developed lorcaserin; licensed to Eisai. Acquired by Pfizer in 2022 |
Litigation Timeline
Jun 2012
FDA approves Belviq (lorcaserin) for chronic weight management
2014-2018
CAMELLIA-TIMI 61 post-marketing safety trial conducted
Feb 2020
Eisai voluntarily withdraws Belviq from US market
2021
First Belviq cancer lawsuits filed
2025-2026
~150 cases filed — pre-MDL consolidation stage
Intelligence Signals
No signals yet. Signals populate automatically when scrapers run.
Key Facts
- Status
- active
Geographic Exposure
·Pre-MDL — cases filed in multiple federal districts
·N.D. Ohio (potential MDL venue)
·California state courts
·Nationwide filing anticipated
Eligibility Criteria
- ✓Took Belviq or Belviq XR (lorcaserin) for weight loss
- ✓Diagnosed with cancer (pancreatic, colorectal, lung, or other) after use
- ✓Cancer diagnosis occurred during or after Belviq treatment
- ✓No prior cancer diagnosis before starting Belviq